Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.44 |
| ▸ | PI4KA | P42356 | 3/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349439 | 0.76 | ADORA2A (0.41) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL21316678 | 0.76 | ADORA2A (0.53) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL756293 | 0.76 | ADORA2A (0.53) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3035399 | 0.73 | ADORA2A (0.42) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10835442 | 0.71 | ADORA2A (0.37) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL26976 | 0.69 | ADORA2A (0.61) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL763189 | 0.68 | ADORA2A (0.53) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL13593762 | 0.67 | LIMK1 (0.44) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1378254 | 0.67 | ADORA2A (0.45) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL18546887 | 0.66 | KDR (0.45) | ADORA2AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340633-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-20170049772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2017-02-23 | — | — | US | disclosed |
| US-9487772-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2016-11-08 | — | — | US | disclosed |
| US-8653077-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-02-18 | — | — | US | disclosed |
| US-8637533-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| US-8623881-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-01-07 | — | — | US | disclosed |
| US-8492389-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120172591-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-05-31 | — | — | US | disclosed |
| US-8138195-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340633-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | ADORA2A 3432/4885ADORA1 2913/4885PI4KA 5/4885 |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | ADORA2A 3432/4885ADORA1 2913/4885PI4KA 5/4885 |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | ADORA2A 3432/4885ADORA1 2913/4885PI4KA 5/4885 |
| US-20170049772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | ADORA2A 3485/4885ADORA1 2944/4885PI4KA 4/4885 |
| US-20120172591-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | ADORA2A 3432/4885ADORA1 2913/4885PI4KA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.